Metronidazole delayed release - Gateway Pharmaceutical
Latest Information Update: 09 Jan 2026
At a glance
- Originator Gateway Pharmaceutical
- Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Clostridium difficile infections
Most Recent Events
- 22 Oct 2025 Adverse events and pharmacokinetics data from a phase I trial in Clostridium difficile infections released by Gateway Pharmaceutical
- 22 Oct 2025 Pharmacokinetics data from the preclinical trials in clostridium difficile infections released by Gateway Pharmaceutical
- 22 Oct 2025 Gateway Pharmaceutical plans a phase III trial in Clostridium difficile infections(PO)